Kidney Neoplasm
27
8
12
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
3 terminated out of 27 trials
66.7%
-19.9% vs benchmark
7%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (27)
Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy
German National Registry for NSS
An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors
Study of Kidney Tumors in Younger Patients
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
SPECT/CT for the Characterization of Renal Masses
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and Stability
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors
Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma